Article citationsMore>>

Arkenau, H.T., Chong, G., Cunningham, D., Watkins, D., Agarwal, R., Sirohi, B., Trumper, M., Norman, A., Wotherspoon, A. and Horwich, A. (2007) The Role of Intrathecal Chemotherapy Prophylaxis in Patients with Diffuse Large B-Cell Lymphoma. Annals of Oncology, 18, 541-545.
https://doi.org/10.1093/annonc/mdl434

has been cited by the following article:

• TITLE: Case Report: Fever of Unknown Origin —An Unusual Presentation for Diffuse Large B-Cell Lymphoma

  AUTHORS: Chidinma Onweni, Jennifer Treece, Christine Moore, Mailien Rogers

  KEYWORDS: Fever of Unknown Origin, Epstein-Barr Virus, Diffuse Large B-Cell Lymphoma, Non-Hodgkin’s Lymphoma

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.4, April 30, 2017

  ABSTRACT: A 61-year-old male initially presented with fever of unknown origin. He had extensive work-up over two years including an infectious diseases panel, autoimmune studies, and Rheumatology and Hematology evaluations. The patient was initially diagnosed with Adult Still’s disease and underwent an out-patient right nodal fine-needle aspiration that was indeterminate. After continued failure of treatment for Adult Still’s disease, the patient had surgical resection of a right axillary lymph node that yielded the diagnosis of diffuse large B-cell lymphoma. Further work-up revealed Epstein-Barr virus positivity, the possible trigger behind his mutation for diffuse large B-cell lymphoma and its uncommon presentation. The patient met criteria for central nervous system prophylaxis and received multiple administrations throughout his therapy. He ultimately expired following recurrence of his disease at its initial site but without central nervous system involvement. We report an uncommon presentation of a patient with diffuse large B-cell lymphoma. This lymphoma can have numerous, vague presentations requiring a broad differential diagnosis and may lead to multiple evaluations prior to an ultimate diagnosis. We will also discuss the need for central nervous system prophylaxis, how this patient is qualified for prophylaxis, and how central nervous system prophylaxis benefits, harms, or does not affect patients with diffuse large B-cell lymphoma.